3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Renal Cell
35
Carcinoma, Hepatocellular
17
Neoplasm Metastasis
15
Prostatic Neoplasms
13
Neoplasms
9
Neuroendocrine Tumors
7
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
6
Brain Neoplasms
6
Sarcoma, Ewing
5
Sarcoma
5
Osteosarcoma
5
Kidney Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Transitional Cell
5
Recurrence
4
Pancreatic Neoplasms
4
Multiple Myeloma
4
Clear-cell metastatic renal cell carcinoma
4
Urinary Bladder Neoplasms
3
Lung Neoplasms
3
Carcinoid Tumor
3
Adenocarcinoma
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Thyroid Diseases
2
Pheochromocytoma
2
Paraganglioma
2
Neurofibroma, Plexiform
2
Melanoma
2
Interventions
pembrolizumab
3
lenvatinib
3
gallium 68 PSMA-11
2
apatinib
2
Protons
2
Magnetic Resonance Spectroscopy
2
Imatinib Mesylate
2
Epirubicin
2
Cisplatin
2
Carboplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
tislelizumab
1
regorafenib
1
enfortumab vedotin
1
cabozantinib
1
avelumab
1
anlotinib
1
amivantamab
1
abemaciclib
1
Tretinoin
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Radiation
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Adenoid Cystic
×
cabozantinib
×
Clear all
NCT03729297
2021-03-12
Cabo ASAP
Radboud University Medical Center
Phase 2
Terminated
25 enrolled